Ostatní
Návod 
Innate Pharma S.A.
IPHA
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
0.2B
Obrat
0B
Zisk
0B
Aktiva
0B
Dluh
0B
ROE
-1617%
ROA
-90%
PE
-1
PS
6
Cena 1R
2-3
⌀ Cena
1.98
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
26-03-2026
Poslední dividenda
Profil
Innate Pharma S.A., biotechnologická společnost, objevuje, vyvíjí a komercializuje terapeutické protilátky pro léčbu onkologických indikací ve Francii a mezinárodně. Mezi produkty společnosti patří Lacutamab (IPH4102), protilátka proti KIR3DL2, která se nachází v klinických studiích fáze II zaměřených na léčbu kožních T-buněk a periferních T-buněčných lymfomů, a dále v klinických studiích fáze II zaměřených na léčbu syndromu refrakterního sézeru; Monalizumab, inhibitor imunitního kontrolního bodu, který je součástí klinické studie fáze III zaměřené na léčbu pokročilých solidních nádorů zahrnujících rakovinu tlustého střeva a plic, jakož i rakovinu hlavy a krku; Avdoralimab (IPH5401), monoklonální protilátka blokující C5a C5aR1, který je součástí klinických studií fáze II pro léčbu COVID-19, bulózní pemfigoid, chronickou spontánní kopřivku a další zánětlivá onemocnění; IPH5201, blokující protilátka, která je v klinických studiích fáze 1 zaměřených na imunosupresivní dráhu CD39; IPH5301, protilátka proti CD73 zaměřená na imunosupresivní adenosinovou dráhu k podpoře protinádorové imunity; a IPH6101, angažant NK buněk založený na NKp46 pro generování a hodnocení až dvou bispegokinů cific NK-buněční engagery. Jeho produkty v předklinických studiích jsou IPH43, konjugát proti MICA/B protilátkám; Anti-Siglec-9, program protilátek; IPH65, tetraspecifická proprietární protilátka; IPH25, kontrolní inhibitor; a programy IPH62 a IPH64. Společnost Innate Pharma S.A. má licenční smlouvy a smlouvy o spolupráci se společnostmi AstraZeneca, Novo Nordisk A/S, Sanofi a Orega Biotech a smlouvu o spolupráci a licenci se společností MedImmune Limited. Společnost byla založena v roce 1999 a sídlí ve francouzském Marseille.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
181
Založení
2019-10-17
Podobné společnosti
$ 1.96
- $ 0.06
$ 4.24
- $ 0.50
$ 6.08
- $ 0.07
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 18.6 | 2.7 | 12.6 | 51.9 | 49.6 | 12.1 | 56.8 | 69.0 | 79.9 | 32.6 | 56.2 | 17.9 | 0.9 | 12.5 | 10.4 | 11.7 | 4.3 | |
| Cost of Revenues | 20.5 | 0.0 | 0.0 | 56.0 | 0.0 | 0.0 | 3.0 | 45.2 | 0.0 | 0.0 | 0.0 | 0.0 | 12.1 | 7.6 | 6.9 | 1.6 | 3.4 | |
| Gross Profit | -3.0 | 0.0 | 12.6 | -4.1 | 49.6 | 12.1 | 53.8 | 23.8 | 79.9 | 32.6 | 56.2 | 17.9 | -11.2 | 4.9 | 3.5 | 10.1 | 0.9 |
| Revenue | 4-2025 | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 1.1 | 4.9 | 0.3 | 12.3 | 6.2 | 10.7 | 10.7 | 35.3 | 20.1 | 18.4 | |
| Cost of Revenues | 0.0 | 20.5 | -29.1 | 29.1 | 14.5 | 12.3 | 12.3 | 15.7 | 15.7 | 15.7 | |
| Gross Profit | 0.0 | -15.7 | 29.4 | -16.7 | -8.4 | -1.6 | -1.6 | 19.6 | 4.4 | 2.6 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 56.0 | 51.7 | 47.0 | 58.6 | 1.6 | 69.6 | 67.0 | 48.6 | 29.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 11.7 | 22.4 | 25.5 | 30.4 | 49.6 | 19.3 | 16.2 | 9.3 | 5.9 | 12.8 | 10.7 | 9.7 | 9.8 | 7.1 | |
| Depreciation & Amortization | 3.0 | 1.3 | 2.0 | 5.1 | 45.4 | 10.9 | 56.8 | 18.2 | 7.4 | 4.4 | 3.3 | 2.7 | 2.3 | 0.9 | 0.8 | 0.9 | 1.1 | |
| Total Operating Expenses | 105.8 | 59.2 | 64.2 | 64.6 | 66.1 | 59.9 | 75.4 | 50.9 | 74.7 | 72.6 | 48.6 | 28.7 | 8.8 | 7.7 | 6.9 | 17.7 | 14.6 | |
| Operating Income | -109.4 | -57.9 | -51.6 | -12.7 | -11.7 | -47.8 | -13.7 | -27.1 | 5.1 | -40.0 | 7.6 | -10.8 | -20.0 | -2.8 | -3.4 | -7.6 | -13.7 |
| Operating Income | TTM | 4-2025 | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 14.5 | 12.3 | 12.3 | 28.4 | 15.7 | 0.0 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 4.8 | 4.6 | 4.6 | 8.5 | 4.6 | 15.7 | ||
| Depreciation & Amortization | 0.7 | 0.4 | 1.2 | 0.8 | 0.4 | 0.9 | 0.9 | 3.6 | 1.6 | 3.4 | ||
| Total Operating Expenses | 31.8 | 9.8 | 54.6 | 9.6 | 4.8 | 4.0 | 4.0 | 37.0 | 3.8 | 15.7 | ||
| Operating Income | -32.4 | -25.4 | -25.3 | -26.3 | -13.2 | -6.1 | -6.1 | -5.3 | -0.2 | -4.2 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 10.3 | 7.6 | 2.4 | 3.2 | 4.8 | 6.3 | 4.9 | 1.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.9 | 0.0 | |
| Interest Expense | 3.5 | 3.0 | 0.6 | 0.6 | 5.3 | 4.0 | 6.8 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.5 | 0.0 | |
| Other Expense | 6.9 | 4.7 | 2.1 | 5.1 | -46.3 | 2.3 | -50.3 | 6.3 | -2.1 | -7.9 | 4.7 | 4.2 | 0.5 | 0.1 | 0.4 | 0.6 | 0.0 | |
| IBT | -101.4 | -53.2 | -49.5 | -7.6 | -58.0 | -45.5 | -64.0 | -20.8 | 2.7 | -48.0 | 12.9 | -6.7 | -19.6 | -2.9 | -3.2 | -7.0 | -13.7 | |
| Income Tax Expense | -3.0 | -6.0 | 0.0 | 0.0 | 41.1 | 13.7 | 6.8 | 0.2 | -0.3 | 0.4 | 0.3 | 0.1 | 0.0 | -0.1 | -0.1 | 1.1 | 0.0 | |
| Net Income | -98.4 | -47.2 | -49.5 | -7.6 | -99.1 | -59.1 | -70.7 | -21.0 | 3.0 | -48.4 | 12.6 | -6.7 | -19.6 | -2.9 | -3.2 | -7.0 | -13.7 |
| Net Income | TTM | 4-2025 | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 7.1 | 0.6 | 0.1 | 2.5 | 0.0 | 6.0 | 0.9 | 1.0 | 0.3 | 0.0 | ||
| Interest Expense | 2.9 | 0.0 | 0.0 | 0.6 | 0.0 | 1.5 | 0.0 | 0.3 | 0.0 | -0.1 | ||
| Other Expense | 0.8 | 4.1 | 0.6 | 1.5 | 0.8 | -8.0 | 1.5 | 2.1 | 1.1 | -1.0 | ||
| IBT | -30.6 | -21.3 | -24.7 | -24.8 | -12.4 | -4.6 | -4.6 | -3.1 | 0.9 | -5.2 | ||
| Income Tax Expense | -3.0 | 0.0 | 0.0 | 0.0 | 0.0 | -4.9 | 0.0 | -4.9 | 0.0 | -1.1 | ||
| Net Income | -27.6 | -21.3 | -24.7 | -24.8 | -12.4 | -4.6 | -4.6 | 1.7 | 0.9 | -5.2 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $-0.09 | $-1.24 | $-0.74 | $-0.90 | $-0.31 | $0.05 | $-0.89 | $0.23 | $-0.13 | $-0.39 | $-0.07 | $-0.08 | $-0.19 | $-0.36 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $-0.09 | $-1.24 | $-0.74 | $-0.90 | $-0.31 | $0.05 | $-0.89 | $0.23 | $-0.13 | $-0.39 | $-0.07 | $-0.08 | $-0.19 | $-0.36 | |
| Shares Outstanding | 91.4 | 89.4 | 81.1 | 80.5 | 79.6 | 79.5 | 78.9 | 66.9 | 58.8 | 54.4 | 53.9 | 53.4 | 50.2 | 38.7 | 37.8 | 37.7 | 37.4 | |
| Diluted Shares Outstanding | 91.4 | 89.4 | 81.1 | 80.5 | 79.6 | 79.5 | 78.9 | 66.9 | 58.8 | 54.4 | 53.9 | 53.4 | 50.2 | 38.7 | 37.8 | 37.7 | 37.4 |
| Per Share Data | TTM | 4-2025 | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $-0.15 | $-0.06 | $-0.06 | $0.02 | $0.01 | $-0.06 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $-0.15 | $-0.06 | $-0.06 | $0.02 | $0.01 | $-0.06 | ||
| Shares Outstanding | 91.4 | 85.4 | 81.1 | 79.9 | 79.9 | 80.6 | 80.6 | 80.3 | 85.9 | 82.3 | ||
| Diluted Shares Outstanding | 91.4 | 86.9 | 81.1 | 80.9 | 80.9 | 80.6 | 80.6 | 83.8 | 83.8 | 82.3 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 70.6 | 66.4 | 70.6 | 84.2 | 103.8 | 136.8 | 202.9 | 152.3 | 99.4 | 175.9 | 152.9 | 64.3 | 38.4 | 30.6 | 46.6 | 31.8 | |
| Short Term Investments | 21.9 | 14.4 | 21.9 | 17.3 | 16.1 | 14.8 | 16.0 | 15.2 | 16.7 | 21.8 | 83.0 | 5.0 | 3.0 | 2.0 | 0.0 | 2.8 | |
| Total Cash & ST Investments | 92.5 | 80.8 | 92.5 | 101.5 | 119.8 | 151.6 | 218.9 | 167.5 | 116.1 | 197.7 | 235.9 | 69.2 | 41.3 | 32.6 | 46.6 | 34.6 | |
| Accounts Receivable | 46.5 | 5.0 | 15.2 | 38.3 | 18.4 | 21.7 | 13.1 | 146.6 | 15.1 | 25.6 | 9.9 | 8.6 | 7.1 | 7.2 | 0.0 | 6.1 | |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 | -21.8 | -18.7 | 5.6 | 0.0 | 6.3 | 0.0 | 0.0 | 1.5 | 0.9 | 1.2 | 0.0 | 0.0 | |
| Other Current Assets | 9.1 | 0.0 | 40.3 | 0.0 | 21.8 | 18.7 | 0.0 | 5.5 | 0.0 | 6.8 | 6.3 | 0.0 | 0.0 | 0.0 | 6.4 | 0.0 | |
| Total Current Assets | 148.0 | 85.7 | 148.0 | 139.8 | 138.3 | 173.3 | 237.6 | 319.6 | 137.5 | 230.1 | 252.1 | 79.3 | 49.4 | 41.0 | 53.0 | 40.7 |
| Current Assets | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 53.7 | 66.4 | 70.0 | 70.0 | 70.6 | 70.6 | 71.4 | 71.4 | 84.2 | 102.9 | |
| Short Term Investments | 6.3 | 14.4 | 21.8 | 21.8 | 21.9 | 21.9 | 17.5 | 17.5 | 17.3 | 20.4 | |
| Total Cash & ST Investments | 60.0 | 80.8 | 91.8 | 91.8 | 92.5 | 92.5 | 88.9 | 88.9 | 101.5 | 123.4 | |
| Accounts Receivable | 0.4 | 5.0 | 0.4 | 0.4 | 46.5 | 15.2 | 2.9 | 2.9 | 38.3 | 41.8 | |
| Inventory | 0.0 | 0.0 | 0.0 | 3.0 | 0.0 | 0.0 | -6.5 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 4.6 | 0.0 | 19.4 | 19.4 | 5.7 | 40.3 | 52.6 | 52.6 | 0.0 | 6.6 | |
| Total Current Assets | 65.0 | 85.7 | 111.6 | 111.6 | 148.0 | 148.0 | 144.5 | 144.5 | 139.8 | 171.8 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 6.3 | 5.1 | 6.3 | 8.5 | 10.2 | 11.7 | 11.7 | 10.2 | 10.7 | 9.1 | 6.3 | 5.9 | 6.3 | 6.8 | 6.4 | 7.3 | |
| Goodwill | 0.0 | 0.0 | 0.0 | -41.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Intangible Assets | 0.4 | 0.0 | 0.4 | 42.6 | 44.2 | 46.3 | 97.0 | 84.5 | 46.2 | 9.1 | 9.7 | 5.4 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 9.8 | 19.6 | 9.8 | 35.1 | 39.9 | 38.9 | 37.0 | 35.2 | 60.5 | 33.0 | 37.8 | 0.0 | 0.3 | 0.5 | 0.0 | 0.0 | |
| Other Long-Term Assets | 10.6 | 0.6 | 19.6 | 14.2 | 30.0 | 30.1 | 16.8 | 0.1 | 0.1 | 0.4 | 37.8 | 0.1 | 0.0 | 0.0 | 0.7 | 0.0 | |
| Total Long-Term Assets | 36.2 | 25.3 | 36.2 | 68.0 | 129.2 | 134.1 | 163.8 | 131.6 | 117.5 | 51.5 | 53.8 | 11.4 | 6.5 | 7.3 | 7.1 | 7.3 | |
| Total Assets | 184.2 | 111.1 | 184.2 | 207.9 | 267.5 | 307.4 | 401.4 | 451.2 | 255.0 | 281.6 | 306.0 | 90.7 | 55.9 | 48.3 | 60.1 | 48.0 |
| Long-Term Assets | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 5.0 | 5.1 | 5.7 | 5.7 | 6.3 | 6.3 | 7.3 | 7.3 | 8.5 | 9.6 | |
| Goodwill | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -41.0 | 0.0 | |
| Intangible Assets | 0.0 | 0.0 | 0.1 | 0.1 | 0.4 | 0.4 | 0.9 | 0.9 | 42.6 | 43.3 | |
| Long-Term Investments | 10.4 | 19.6 | 10.4 | 10.4 | 9.8 | 9.8 | 35.8 | 35.8 | 35.1 | 34.8 | |
| Other Long-Term Assets | 12.6 | 0.6 | 14.6 | 23.7 | 10.6 | 19.6 | 1.0 | 10.6 | 14.2 | 13.2 | |
| Total Long-Term Assets | 28.0 | 25.3 | 39.9 | 39.9 | 36.2 | 36.2 | 54.6 | 54.6 | 68.0 | 108.6 | |
| Total Assets | 92.9 | 111.1 | 151.5 | 151.5 | 184.2 | 184.2 | 199.0 | 199.0 | 207.9 | 280.4 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 8.6 | 16.0 | 8.6 | 20.9 | 28.6 | 29.5 | 27.9 | 41.7 | 20.0 | 15.6 | 59.5 | 6.8 | 5.1 | 4.7 | 0.0 | 6.7 | |
| Short-Term Debt | 8.9 | 9.0 | 8.9 | 2.1 | 30.7 | 2.1 | 2.1 | 1.3 | 1.3 | 1.3 | 0.6 | 0.5 | 0.6 | 1.2 | 13.2 | 0.7 | |
| Other Current Liabilities | 16.3 | 7.4 | 15.1 | 11.8 | 8.1 | 2.5 | 43.0 | 71.6 | 4.7 | 4.7 | 0.0 | 2.6 | 2.3 | 1.9 | 2.3 | 0.7 | |
| Current Liabilities | 39.6 | 33.0 | 39.6 | 41.3 | 79.9 | 46.7 | 121.8 | 196.7 | 73.9 | 76.4 | 60.2 | 10.8 | 9.3 | 15.4 | 15.5 | 7.4 |
| Current Liabilities | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 4.6 | 16.0 | 8.8 | 8.8 | 8.6 | 8.6 | 9.9 | 9.9 | 20.9 | 12.9 | |
| Short-Term Debt | 8.9 | 9.0 | 8.9 | 8.9 | 8.9 | 8.9 | 5.3 | 5.3 | 2.1 | 30.9 | |
| Other Current Liabilities | 15.9 | 7.4 | 17.7 | 20.5 | 9.3 | 22.1 | 17.4 | 22.5 | 11.8 | 20.7 | |
| Current Liabilities | 29.4 | 33.0 | 38.2 | 38.2 | 39.6 | 39.6 | 37.7 | 37.7 | 41.3 | 73.6 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 30.6 | 22.4 | 31.0 | 40.1 | 13.5 | 16.9 | 16.6 | 3.2 | 4.5 | 4.1 | 3.1 | 3.8 | 4.2 | 3.3 | 0.0 | 6.8 | |
| Capital Leases | 0.4 | 0.4 | 0.8 | 2.1 | 2.8 | 3.5 | 3.1 | 2.1 | 3.0 | 3.9 | 2.3 | 2.7 | 3.2 | 3.8 | 0.0 | 0.0 | |
| Def. Tax Liability | 9.0 | 0.0 | 0.0 | 8.6 | 5.0 | 7.1 | 1.3 | 1.6 | 3.6 | 2.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 132.3 | 102.2 | 132.3 | 153.7 | 160.1 | 151.4 | 183.9 | 284.0 | 169.1 | 195.4 | 233.9 | 16.1 | 15.6 | 24.9 | 33.5 | 14.5 |
| Long-Term Liabilities | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 18.1 | 22.4 | 26.6 | 26.6 | 31.0 | 31.0 | 35.3 | 35.3 | 40.1 | 12.5 | |
| Capital Leases | 0.6 | 0.4 | 0.6 | 0.6 | 0.4 | 0.8 | 1.1 | 1.1 | 2.1 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 9.1 | 0.0 | 9.0 | 0.0 | 9.7 | 0.0 | 8.6 | 7.8 | |
| Total Liabilities | 87.8 | 102.2 | 122.7 | 122.7 | 132.3 | 132.3 | 141.2 | 141.2 | 153.7 | 164.1 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 4.0 | 4.2 | 4.0 | 4.0 | 4.0 | 4.0 | 3.9 | 3.2 | 2.9 | 2.7 | 2.7 | 2.6 | 2.3 | 1.9 | 1.9 | 1.9 | |
| Retained Earnings | -336.9 | -386.4 | -336.9 | -330.3 | -272.2 | -220.5 | -155.7 | -134.8 | -152.0 | -103.6 | -116.2 | -109.5 | -90.0 | -87.1 | -7.0 | -76.9 | |
| Comprehensive Income | 0.5 | 0.0 | 0.5 | 0.8 | 0.5 | 0.4 | -0.5 | -1.1 | 0.2 | -0.5 | -0.7 | -0.2 | 0.0 | 0.0 | 0.0 | 0.3 | |
| Total Common Equity | 51.9 | 8.8 | 51.9 | 54.2 | 107.4 | 156.0 | 217.4 | 167.2 | 86.0 | 86.2 | 72.1 | 74.6 | 40.3 | 23.4 | 26.6 | 33.5 |
| Total Common Equity | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 4.6 | 4.2 | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | |
| Retained Earnings | -407.7 | -386.4 | -361.7 | -361.7 | -336.9 | -336.9 | -328.6 | -328.6 | -330.3 | -265.9 | |
| Comprehensive Income | 1.2 | 0.0 | 0.4 | 0.4 | 0.5 | 0.5 | 1.1 | 1.1 | 0.8 | 0.3 | |
| Total Common Equity | 5.1 | 8.8 | 28.8 | 28.8 | 51.9 | 51.9 | 57.9 | 57.9 | 54.2 | 116.3 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 39.9 | 31.4 | 39.9 | 42.3 | 44.3 | 19.1 | 18.7 | 4.5 | 5.9 | 5.3 | 3.8 | 4.2 | 4.8 | 4.5 | 13.2 | 6.8 | |
| Book Value | 51.9 | 8.8 | 51.9 | 54.2 | 107.4 | 156.0 | 217.4 | 167.2 | 86.0 | 86.2 | 72.1 | 74.6 | 40.3 | 23.4 | 26.6 | 33.5 |
| Other | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 4-2022 | 2-2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 5.1 | 8.8 | 28.8 | 28.8 | 51.9 | 51.9 | 57.9 | 57.9 | 54.2 | 116.3 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -6.7 | -47.2 | -49.5 | -7.6 | -58.1 | -52.8 | -64.0 | -20.8 | 3.0 | -48.4 | 12.6 | -6.7 | -19.6 | -2.9 | -3.2 | -7.0 | -13.7 | |
| Depreciation & Amortization | 6.9 | 1.3 | 2.0 | 5.1 | 45.4 | 4.6 | 56.8 | 16.5 | 7.4 | 4.4 | 3.3 | 2.7 | 2.3 | 0.9 | 0.8 | 0.9 | 1.1 | |
| Stock-Based Compensation | 4.3 | 0.0 | 3.9 | 4.3 | 4.2 | 2.6 | 2.5 | 3.8 | 2.7 | 9.8 | 1.0 | 1.0 | 0.4 | 0.3 | 0.0 | 0.2 | 0.0 | |
| Change Working Capital | -37.2 | -10.2 | 39.2 | -32.1 | -12.5 | -9.9 | -49.2 | 40.2 | -47.1 | -17.0 | -50.8 | 211.5 | -1.3 | -9.4 | -8.6 | 19.1 | -0.7 | |
| Change In Accounts Receivable | -15.7 | 0.0 | 0.0 | 0.0 | -4.2 | 3.4 | -22.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.1 | 0.4 | -2.0 | 0.0 | 0.0 | |
| Change In Accounts Payable | -3.9 | 0.0 | 0.0 | -3.9 | -7.7 | -0.9 | -6.5 | 1.4 | 0.0 | 0.0 | 7.9 | 9.2 | 1.7 | -5.5 | 1.0 | 0.0 | 0.0 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -6.3 | 25.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Non-cash Items | 10.3 | 5.4 | -2.5 | -2.2 | 1.8 | -1.3 | -0.5 | -0.8 | 0.3 | -0.1 | -0.4 | 0.0 | 0.2 | 0.1 | 0.4 | -0.3 | 0.0 | |
| Cash from Operations | -38.3 | 0.0 | 0.0 | -32.6 | -19.2 | -58.5 | -51.8 | 34.9 | -32.5 | -48.1 | -36.9 | 207.9 | -18.1 | -11.0 | -10.5 | 13.0 | -13.4 |
| Cash Flow From Operating Activities | 4-2025 | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -27.6 | -21.3 | -24.7 | -24.8 | -12.4 | -4.6 | -4.6 | 1.7 | 0.9 | -5.2 | |
| Depreciation & Amortization | 0.7 | 0.7 | 0.9 | 1.1 | 0.6 | 0.7 | 0.7 | 3.6 | 1.8 | 3.4 | |
| Stock-Based Compensation | 0.0 | 1.6 | 2.2 | 1.7 | 0.9 | 1.4 | 1.4 | 0.7 | 0.7 | 0.0 | |
| Change Working Capital | 2.6 | -10.0 | 7.9 | 31.3 | 15.7 | -6.5 | -6.5 | -18.5 | -5.6 | -35.7 | |
| Change In Accounts Receivable | 0.0 | -2.7 | -31.8 | 31.8 | 15.9 | -4.8 | -4.8 | -4.0 | -2.0 | -5.3 | |
| Change In Accounts Payable | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.9 | 0.0 | 0.0 | |
| Change In Inventories | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Non-cash Items | 0.9 | -2.1 | 3.8 | -6.4 | -3.2 | -1.5 | -1.5 | 16.9 | -3.5 | 37.5 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 1.5 | -10.5 | -10.5 | -11.5 | -5.7 | 0.0 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.5 | -0.1 | -0.4 | -0.4 | -1.1 | -1.3 | -11.3 | -65.4 | -1.4 | -6.0 | -9.4 | -7.4 | -2.3 | -0.4 | -1.2 | -0.3 | -0.4 | |
| Acquisitions | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.1 | 8.0 | 0.0 | -0.1 | -0.1 | 0.0 | 0.0 | 0.0 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -3.0 | 0.0 | 0.0 | -43.3 | -18.2 | -121.9 | -2.0 | -3.0 | -2.0 | 0.0 | 0.0 | |
| Sales of Investment | 22.8 | 13.5 | 9.6 | 22.8 | 3.0 | 0.0 | 0.0 | 2.0 | 25.7 | 19.8 | 88.1 | 7.0 | 0.5 | 2.5 | 0.0 | 2.8 | 0.0 | |
| Other Investing Activities | 21.0 | 0.0 | 0.0 | -1.8 | 0.0 | 0.4 | 0.9 | 1.3 | 0.0 | -3.1 | -8.0 | 0.0 | 0.0 | 0.1 | -0.2 | 0.0 | 0.1 | |
| Cash from Investing | 20.5 | 0.0 | 0.0 | 20.6 | 1.9 | -0.9 | -13.4 | -62.1 | 24.3 | -29.5 | 60.5 | -122.3 | -3.8 | -1.0 | -3.4 | 2.4 | -0.3 |
| Cash Flow From Investing Activities | 4-2025 | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -0.1 | -0.1 | -0.1 | -0.3 | -0.1 | 0.0 | 0.0 | -0.3 | -0.2 | -0.3 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Investments | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Sales of Investment | 7.3 | 0.0 | 9.6 | 0.0 | 0.0 | 22.8 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 | 10.5 | 10.5 | 0.1 | 0.0 | 0.6 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | 10.4 | 10.4 | -0.2 | -0.1 | 0.4 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | -2.4 | 0.0 | 0.0 | -2.4 | -2.0 | -2.1 | -2.2 | -2.0 | -1.3 | -1.2 | -0.7 | -0.5 | -0.6 | -1.2 | -2.3 | -0.7 | -0.8 | |
| Debt Issued | 0.0 | 31.4 | -8.5 | 0.0 | 0.0 | 27.2 | 2.6 | 16.2 | 0.0 | 1.7 | 2.3 | 0.0 | 0.0 | 1.5 | -6.5 | 7.2 | 7.6 | |
| Issuance of Common Stock | 0.4 | 0.0 | 0.0 | 0.4 | 0.0 | 0.0 | 0.0 | 66.0 | 62.6 | 0.0 | 0.0 | 0.1 | 47.8 | 19.1 | 0.1 | 0.1 | 0.0 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | -0.1 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.9 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -2.0 | 0.0 | 0.0 | 0.4 | 0.2 | 28.9 | 1.1 | 13.7 | 0.0 | 2.1 | 0.1 | 3.4 | 1.7 | 1.8 | 0.0 | 0.0 | 0.0 | |
| Cash from Financing | -2.6 | 0.0 | 0.0 | -2.0 | -1.8 | 26.8 | -1.1 | 77.8 | 61.2 | 0.9 | -0.6 | 3.0 | 48.0 | 19.7 | -2.1 | -0.7 | -0.9 |
| Cash Flow From Financing Activities | 4-2025 | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -0.5 | |
| Debt Issued | 0.0 | 27.0 | 31.4 | 0.6 | -5.0 | 0.5 | -1.3 | 0.6 | -2.1 | 19.3 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | 0.0 | 0.0 | |
| Repurchase of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | -2.2 | -0.8 | -0.4 | -1.2 | -0.6 | -0.1 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | -2.2 | -0.4 | -0.4 | -1.2 | -0.6 | -0.6 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -20.4 | -30.4 | -4.2 | -13.6 | -19.5 | -33.0 | -66.1 | 50.6 | 52.9 | -76.5 | 23.0 | 88.6 | 25.9 | 7.8 | -16.0 | 14.8 | -14.6 | |
| Closing Cash Balance | 70.6 | 28.1 | 66.4 | 70.6 | 84.2 | 103.8 | 136.8 | 202.9 | 152.3 | 99.4 | 175.9 | 152.9 | 64.3 | 38.4 | 30.6 | 46.6 | 31.8 |
| Cash position | 4-2025 | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -25.6 | 53.7 | -3.6 | 70.0 | -0.3 | -0.8 | -0.4 | -12.8 | -6.4 | -0.2 | |
| Closing Cash Balance | 28.1 | 53.7 | 66.4 | 70.0 | -0.3 | 70.6 | -0.4 | 71.4 | -6.4 | -0.2 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -38.8 | -50.8 | -7.3 | -34.9 | -20.3 | -59.8 | -63.1 | -30.5 | -34.0 | -54.1 | -46.2 | 200.5 | -20.5 | -11.4 | -11.7 | 12.7 | -13.9 | |
| Real Free Cash Flow | -43.1 | -50.8 | -11.2 | -39.2 | -24.5 | -62.4 | -65.6 | -34.3 | -36.7 | -63.9 | -47.3 | 199.5 | -20.9 | -11.7 | -11.7 | 12.4 | -13.9 |
| Free Cash Flow | 4-2025 | 2-2025 | 4-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | 1-2023 | 2-2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -23.5 | -31.2 | -10.0 | 2.8 | 1.4 | -10.6 | -10.6 | -11.8 | -5.9 | -0.3 | |
| Real Free Cash Flow | -23.5 | -32.8 | -12.3 | 1.0 | 0.5 | -12.0 | -12.0 | -12.5 | -6.6 | -0.3 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | -1.1 | -43.2 | -1.4 |
| P/S | 5.8 | 11.7 | 9.4 |
| P/B | 20.8 | 6.4 | 5.2 |
| P/FCF | -1.6 | -663.5 | -1.5 |
| Market cap | $0.2 | $0.2 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 29.1 % | 20.1 % | 0 % |
| Debt to Income | -27.5 % | -527.5 % | 0 % |
| Debt to Free cash flow | -40.1 % | -76.2 % | 0 % |
| Interest expense percentage | -3.2 % | -3.1 % | 44.7 % |
| Current ratio | 2.2 | 2.9 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | -1913.7 % | -359.7 % | 0 % |
| ROA | -105.9 % | -25.3 % | 0 % |
| CapEx to Revenue | 2.5 % | 1.4 % | 0 % |
| RaD to Revenue | 0 % | 75.9 % | 0 % |
| ROEM | 102,700.2 | 227534.8 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | -48.2 % | -8.3 % | 68.7 % |
| Operating margin | -381.2 % | -113.9 % | 35.5 % |
| Net margin | -351.7 % | -101.7 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 86.9 mil | 82.9 mil |
| Employee count | 0.2 tis | 0.2 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
